{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T13:00:19Z","timestamp":1648904419209},"reference-count":47,"publisher":"Walter de Gruyter GmbH","issue":"s52","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p id=\"P2_w2aab3b7c23b1b6b1aab1c16b1Aa\">Middle-aged patients with type 2 diabetes mellitus may have languished on monotherapy or a stable therapy for a substantial period without reconsideration of comorbidities or current control of glycated hemoglobin A<jats:sub>1c<\/jats:sub> (HbA<jats:sub>1c<\/jats:sub>). In many patients who lose glycemic control, postprandial hyperglycemia has not been addressed. This is especially true when HbA<jats:sub>1c<\/jats:sub> levels are close to\u2014but not at\u2014goal. Glucagon-like peptide-1 receptor agonists are injectable agents that can be added to oral therapy to address postprandial hyperglycemia. These agents may be a useful alternative to insulin therapy as add-on therapy when dual oral therapy is no longer sufficient and additional glucose lowering is required. Compared with insulin, glucagon-like peptide-1 receptor agonists have provided comparable glucose lowering with less hypoglycemia and without weight gain.<\/jats:p>","DOI":"10.7556\/jaoa.2014.085","type":"journal-article","created":{"date-parts":[[2014,4,23]],"date-time":"2014-04-23T16:30:45Z","timestamp":1398270645000},"page":"14-21","source":"Crossref","is-referenced-by-count":1,"title":["Managing Loss of Glycemic Control in Middle-Aged Patients With Diabetes: The Role of GLP-1 Receptor Agonists in Combination-Therapy Regimens"],"prefix":"10.1515","volume":"114","author":[{"given":"Thomas B.","family":"Repas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2014,5,1]]},"reference":[{"key":"2021042020280635941_j_jaoa.2014.085_ref_001_w2aab3b7c23b1b6b1ab2b1b1Aa","unstructured":"National Diabetes Fact Sheet, 2011. Centers for Disease Control and Prevention website. http:\/\/www.cdc.gov\/diabetes\/pubs\/factsheet11.htm. Accessed January 30, 2014."},{"issue":"17","key":"2021042020280635941_j_jaoa.2014.085_ref_002_w2aab3b7c23b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMsa1213829","article-title":"Achievement of goals in U.S. diabetes care, 1999-2010","volume":"368","author":"Ali","year":"2013","journal-title":"N Engl J Med."},{"issue":"suppl 1","key":"2021042020280635941_j_jaoa.2014.085_ref_003_w2aab3b7c23b1b6b1ab2b1b3Aa","first-page":"S14","article-title":"Standards of medical care in diabetes\u20142014","volume":"37","year":"2014","journal-title":"Diabetes Care"},{"issue":"4","key":"2021042020280635941_j_jaoa.2014.085_ref_004_w2aab3b7c23b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1751-7176.2011.00434.x","article-title":"Comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection","volume":"13","author":"Long","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"4","key":"2021042020280635941_j_jaoa.2014.085_ref_005_w2aab3b7c23b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S1098-3597(09)80002-1","article-title":"Obesity as a disease state: a new paradigm for diagnosis and treatment","volume":"9","author":"Aronne","year":"2009","journal-title":"Clin Cornerstone"},{"issue":"suppl 2","key":"2021042020280635941_j_jaoa.2014.085_ref_006_w2aab3b7c23b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","first-page":"116S","DOI":"10.1038\/oby.2002.204","article-title":"Management of obesity as a chronic disease: nonpharmacologic, pharmacologic, and surgical options","volume":"10","author":"Fujioka","year":"2002","journal-title":"Obes Res"},{"issue":"3","key":"2021042020280635941_j_jaoa.2014.085_ref_007_w2aab3b7c23b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2337\/diacare.26.3.881","article-title":"Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c","volume":"26","author":"Monnier","year":"2003","journal-title":"Diabetes Care"},{"key":"2021042020280635941_j_jaoa.2014.085_ref_008_w2aab3b7c23b1b6b1ab2b1b8Aa","volume-title":"2011 Guideline for Management of Postmeal Glucose","year":"2011"},{"issue":"2","key":"2021042020280635941_j_jaoa.2014.085_ref_009_w2aab3b7c23b1b6b1ab2b1b9Aa","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4158\/endp.19.2.a38267720403k242","article-title":"AACE comprehensive diabetes management algorithm 2013","volume":"19","author":"Garber","year":"2013","journal-title":"Endocr Pract."},{"issue":"3","key":"2021042020280635941_j_jaoa.2014.085_ref_010_w2aab3b7c23b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","first-page":"536","DOI":"10.4158\/EP13176.CS","article-title":"American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement\u2014executive summary","volume":"19","author":"Garber","year":"2013","journal-title":"Endocr Pract."},{"key":"2021042020280635941_j_jaoa.2014.085_ref_011_w2aab3b7c23b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","DOI":"10.1111\/dom.12264","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with T2DM inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-inferiority trial","author":"Kobayashi","year":"2014","journal-title":"Diabetes Obes Metab."},{"issue":"7 suppl 5","key":"2021042020280635941_j_jaoa.2014.085_ref_012_w2aab3b7c23b1b6b1ab2b1c12Aa","first-page":"S20","article-title":"Novel incretin-based agents and practical regimens to meet needs and treatment goals of patients with type 2 diabetes mellitus","volume":"111","author":"Garber","year":"2011","journal-title":"J Am Osteopath Assoc."},{"issue":"4","key":"2021042020280635941_j_jaoa.2014.085_ref_013_w2aab3b7c23b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1742-1241.2011.02656.x","article-title":"One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial","volume":"65","author":"Pratley","year":"2011","journal-title":"Int J Clin Pract."},{"issue":"3","key":"2021042020280635941_j_jaoa.2014.085_ref_014_w2aab3b7c23b1b6b1ab2b1c14Aa","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3810\/pgm.2013.05.2661","article-title":"Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data","volume":"125","author":"Malloy","year":"2013","journal-title":"Postgrad Med."},{"issue":"2","key":"2021042020280635941_j_jaoa.2014.085_ref_015_w2aab3b7c23b1b6b1ab2b1c15Aa","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2337\/dc11-1107","article-title":"Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study","volume":"35","author":"Russell-Jones","year":"2012","journal-title":"Diabetes Care"},{"issue":"6","key":"2021042020280635941_j_jaoa.2014.085_ref_016_w2aab3b7c23b1b6b1ab2b1c16Aa","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/j.1464-5491.2011.03301.x","article-title":"DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide","volume":"28","author":"Wysham","year":"2011","journal-title":"Diabet Med."},{"issue":"6","key":"2021042020280635941_j_jaoa.2014.085_ref_017_w2aab3b7c23b1b6b1ab2b1c17Aa","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.clinthera.2012.04.013","article-title":"Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review","volume":"34","author":"Aroda","year":"2012","journal-title":"Clin Ther."},{"key":"2021042020280635941_j_jaoa.2014.085_ref_018_w2aab3b7c23b1b6b1ab2b1c18Aa","volume-title":"Byetta (exenatide) injection [package insert]","year":"2011"},{"key":"2021042020280635941_j_jaoa.2014.085_ref_019_w2aab3b7c23b1b6b1ab2b1c19Aa","volume-title":"Victoza (liraglutide [rDNA origin] injection) [package insert]","year":"2013"},{"key":"2021042020280635941_j_jaoa.2014.085_ref_020_w2aab3b7c23b1b6b1ab2b1c20Aa","volume-title":"Bydureon (exenatide extended-release for injectable suspension) [package insert]","year":"2012"},{"issue":"1","key":"2021042020280635941_j_jaoa.2014.085_ref_021_w2aab3b7c23b1b6b1ab2b1c21Aa","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"issue":"2","key":"2021042020280635941_j_jaoa.2014.085_ref_022_w2aab3b7c23b1b6b1ab2b1c22Aa","first-page":"183","article-title":"Insulin management of type 2 diabetes mellitus","volume":"84","author":"Petznick","year":"2011","journal-title":"Am Fam Physician"},{"issue":"4 suppl 2","key":"2021042020280635941_j_jaoa.2014.085_ref_023_w2aab3b7c23b1b6b1ab2b1c23Aa","first-page":"S6","article-title":"Identifying and addressing barriers to insulin acceptance and adherence in patients with type 2 diabetes mellitus","volume":"113","author":"Petznick","year":"2013","journal-title":"J Am Osteopath Assoc."},{"issue":"9833","key":"2021042020280635941_j_jaoa.2014.085_ref_024_w2aab3b7c23b1b6b1ab2b1c24Aa","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1016\/S0140-6736(12)60439-5","article-title":"Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial","volume":"379","author":"Aschner","year":"2012","journal-title":"Lancet"},{"issue":"8","key":"2021042020280635941_j_jaoa.2014.085_ref_025_w2aab3b7c23b1b6b1ab2b1c25Aa","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/dom.12115","article-title":"Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents","volume":"15","author":"Philis-Tsimikas","year":"2013","journal-title":"Diabetes Obes Metab."},{"issue":"11","key":"2021042020280635941_j_jaoa.2014.085_ref_026_w2aab3b7c23b1b6b1ab2b1c26Aa","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/j.1463-1326.2011.01436.x","article-title":"Glucagon-like peptide-1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta-analysis of clinical trials","volume":"13","author":"Wang","year":"2011","journal-title":"Diabetes Obes Metab."},{"issue":"3","key":"2021042020280635941_j_jaoa.2014.085_ref_027_w2aab3b7c23b1b6b1ab2b1c27Aa","first-page":"168","article-title":"Insulin vs GLP-1 analogues in poorly controlled Type 2 diabetic subjects on oral therapy: a meta-analysis","volume":"36","author":"Abdul-Ghani","year":"2013","journal-title":"J Endocrinol Invest."},{"issue":"2","key":"2021042020280635941_j_jaoa.2014.085_ref_028_w2aab3b7c23b1b6b1ab2b1c28Aa","first-page":"e62","article-title":"Choice of therapy in patients with type 2 diabetes inadequately controlled with metformin and a sulphonylurea: a systematic review and mixed-treatment comparison meta-analysis","volume":"6","author":"McIntosh","year":"2012","journal-title":"Open Med."},{"key":"2021042020280635941_j_jaoa.2014.085_ref_029_w2aab3b7c23b1b6b1ab2b1c29Aa","volume-title":"FDA requires removal of some prescribing and dispensing restrictions for rosiglitazone-containing diabetes medicines [safety announcement]","year":"2013"},{"issue":"8","key":"2021042020280635941_j_jaoa.2014.085_ref_030_w2aab3b7c23b1b6b1ab2b1c30Aa","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.clinthera.2008.08.006","article-title":"Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study","volume":"30","author":"Moretto","year":"2008","journal-title":"Clin Ther."},{"issue":"10","key":"2021042020280635941_j_jaoa.2014.085_ref_031_w2aab3b7c23b1b6b1ab2b1c31Aa","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1185\/03007990802418851","article-title":"Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study","volume":"24","author":"DeFronzo","year":"2008","journal-title":"Curr Med Res Opin."},{"issue":"13","key":"2021042020280635941_j_jaoa.2014.085_ref_032_w2aab3b7c23b1b6b1ab2b1c32Aa","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1517\/14656566.2010.497142","article-title":"Comparison of once-weekly with twice-daily exenatide in the treatment of type 2 diabetes (DURATION-1 trial)","volume":"11","author":"Raskin","year":"2010","journal-title":"Expert Opin Pharmacother."},{"issue":"6","key":"2021042020280635941_j_jaoa.2014.085_ref_033_w2aab3b7c23b1b6b1ab2b1c33Aa","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.2337\/dc09-2260","article-title":"Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents","volume":"33","author":"Buse","year":"2010","journal-title":"Diabetes Care"},{"issue":"9683","key":"2021042020280635941_j_jaoa.2014.085_ref_034_w2aab3b7c23b1b6b1ab2b1c34Aa","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"2021042020280635941_j_jaoa.2014.085_ref_035_w2aab3b7c23b1b6b1ab2b1c35Aa","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3803\/EnM.2013.28.4.262","article-title":"Clinical application of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus","volume":"28","author":"Cho","year":"2013","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"1","key":"2021042020280635941_j_jaoa.2014.085_ref_036_w2aab3b7c23b1b6b1ab2b1c36Aa","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/jcpt.12102","article-title":"The cardiovascular effects of glucagon-like peptide-1 receptor agonists: a trial sequential analysis of randomized controlled trials","volume":"39","author":"Wu","year":"2014","journal-title":"J Clin Pharm Ther."},{"issue":"1","key":"2021042020280635941_j_jaoa.2014.085_ref_037_w2aab3b7c23b1b6b1ab2b1c37Aa","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/ajh\/hpt196","article-title":"Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression","volume":"27","author":"Katout","year":"2014","journal-title":"Am J Hypertens."},{"issue":"6","key":"2021042020280635941_j_jaoa.2014.085_ref_038_w2aab3b7c23b1b6b1ab2b1c38Aa","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.diabet.2011.07.001","article-title":"Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system","volume":"37","author":"Verg\u00e8s","year":"2011","journal-title":"Diabetes Metab."},{"issue":"3","key":"2021042020280635941_j_jaoa.2014.085_ref_039_w2aab3b7c23b1b6b1ab2b1c39Aa","first-page":"57","article-title":"Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women [letter]","volume":"9","author":"Sears","year":"2007","journal-title":"MedGenMed"},{"issue":"9","key":"2021042020280635941_j_jaoa.2014.085_ref_040_w2aab3b7c23b1b6b1ab2b1c40Aa","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.297.9.969","article-title":"Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trial","volume":"297","author":"Gardner","year":"2007","journal-title":"JAMA"},{"issue":"9590","key":"2021042020280635941_j_jaoa.2014.085_ref_041_w2aab3b7c23b1b6b1ab2b1c41Aa","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","article-title":"Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial","volume":"370","author":"Patel","year":"2007","journal-title":"Lancet"},{"issue":"1","key":"2021042020280635941_j_jaoa.2014.085_ref_042_w2aab3b7c23b1b6b1ab2b1c42Aa","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jama.293.1.43","article-title":"Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial","volume":"293","author":"Dansinger","year":"2005","journal-title":"JAMA"},{"issue":"7-8","key":"2021042020280635941_j_jaoa.2014.085_ref_043_w2aab3b7c23b1b6b1ab2b1c43Aa","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.nut.2012.12.021","article-title":"Effects of Dietary Approaches to Stop Hypertension (DASH) diet on some risk for developing type 2 diabetes: a systematic review and meta-analysis on controlled clinical trials","volume":"29","author":"Shirani","year":"2013","journal-title":"Nutrition"},{"key":"2021042020280635941_j_jaoa.2014.085_ref_044_w2aab3b7c23b1b6b1ab2b1c44Aa","article-title":"The effect of DASH diet on pregnancy outcomes in gestational diabetes: a randomized controlled clinical trial","author":"Asemi","journal-title":"Eur J Clin Nutr."},{"issue":"11","key":"2021042020280635941_j_jaoa.2014.085_ref_045_w2aab3b7c23b1b6b1ab2b1c45Aa","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.2337\/dc13-2042","article-title":"Nutrition therapy recommendations for the management of adults with diabetes","volume":"36","author":"Evert","year":"2013","journal-title":"Diabetes Care"},{"issue":"12","key":"2021042020280635941_j_jaoa.2014.085_ref_046_w2aab3b7c23b1b6b1ab2b1c46Aa","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.2337\/dc10-1548","article-title":"Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement executive summary","volume":"33","author":"Colberg","year":"2010","journal-title":"Diabetes Care"},{"issue":"suppl 2","key":"2021042020280635941_j_jaoa.2014.085_ref_047_w2aab3b7c23b1b6b1ab2b1c47Aa","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.2337\/dc11-s220","article-title":"Hypoglycemia and cardiovascular risks","volume":"34","author":"Frier","year":"2011","journal-title":"Diabetes Care"}],"container-title":["Journal of Osteopathic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.7556\/jaoa.2014.085\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.7556\/jaoa.2014.085\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T10:05:54Z","timestamp":1619172354000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.7556\/jaoa.2014.085\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,1]]},"references-count":47,"journal-issue":{"issue":"s52","published-online":{"date-parts":[[2014,5,1]]},"published-print":{"date-parts":[[2014,5,1]]}},"alternative-id":["10.7556\/jaoa.2014.085"],"URL":"https:\/\/doi.org\/10.7556\/jaoa.2014.085","relation":{},"ISSN":["2702-3648"],"issn-type":[{"value":"2702-3648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,1]]}}}